<body><a name="drugname"></a><table class="topbox" width="100%">
<tr>
<td><span class="topboxgenname">RIZATRIPTAN BENZOATE</span><br/>(ri-za-trip'tan ben'zo-ate)<br/><span class="topboxtradename">Maxalt, </span><span class="topboxtradename">Maxalt-MLT<br/></span><b>Classifications:</b> <span class="classification">autonomic nervous system agent</span>; <span class="classification">adrenergic antagonist (sympatholytic); serotonin 5-ht<sub>ib/id</sub> receptor agonist</span><br/><b>Prototype: </b>Sumatriptan<br/><b>Pregnancy Category: </b>C<br/></td>
</tr>
</table>
<h1><a name="avail">Availability</a></h1>
<p>5 mg, 10 mg tablets; 5 mg, 10 mg disintegrating tablets</p>
<h1><a name="action">Actions</a></h1>
<p>Selective (5-HT<sub>1B/1D</sub>) receptor agonist. The agonist effects at 5-HT<sub>1B/1D</sub> reverse the vasodilation of cranial blood vessels associated with a migraine.
      </p>
<h1><a name="therapef">Therapeutic Effects</a></h1>
<p>Activation of the 5-HT<sub>1B/1D</sub> receptors reduces the pain pathways associated with the migraine headache as well as reversing vasodilation of cranial blood
         vessels.
      </p>
<h1><a name="uses">Uses</a></h1>
<p>Acute migraine headaches with or without aura.</p>
<h1><a name="contrain">Contraindications</a></h1>
<p>Hypersensitivity to rizatriptan; CAD; Prinzmetal's angina (potential for vasospasm); risk factors for CAD such as hypertension,
         hypercholesterolemia, obesity, diabetes, smoking, and strong family history; concurrent administration with ergotamine drugs
         or sumatriptan; concurrent administration with <small>MAOI</small>s; basilar or hemiplegic migraine.
      </p>
<h1><a name="precaution">Cautious Use</a></h1>
<p>Hypersensitivity to sumatriptan; renal or hepatic impairment; pregnancy (category C), lactation; hypertension; asthmatic patients.
         Safety and effectiveness in patients 
      </p><h1><a name="rtedsg">Route &amp; Dosage</a></h1>
<table cellpadding="4" cellspacing="0" class="rdbox" width="100%">
<tr>
<td><span class="indicationtitle">Acute Migraine</span><br/><span class="rdage">Adult:</span> <span class="rdroute">PO</span> 510 mg, may repeat in 2 h if necessary (max: 30 mg/24 h); 5 mg with concurrent propranolol (max: 15 mg/24 h)<br/></td>
</tr>
</table>
<h1><a name="admintn">Administration</a></h1><span class="adminroutetype">Oral</span><br/><ul>
<li>Give any time after symptoms of migraine appear. If symptoms return, a second tablet may be given but no sooner than 2 h after
            the first.
         </li>
<li>Do not exceed 30 mg (three doses) in any 24 h period.</li>
<li>Do not give within 24 h of an ergot-containing drug or another 5-HT<sub>1</sub> agonist.
         </li>
<li>Store at 15°30° C (59°86° F) and protect from light and moisture.</li>
</ul>
<h1><a name="adverse">Adverse Effects (<img src="../images/special/greaterorequal.gif"/>1%)</a></h1><span class="typehead">Body as a Whole:</span> Asthenia, fatigue, pain, pressure sensation, paresthesias, throat pressure, warm/cold sensations. <span class="typehead">CNS:</span> Somnolence, dizziness, headache, hypesthesia, decreased mental acuity, euphoria, tremor. <span class="typehead">CV:</span> Coronary artery vasospasm, transient myocardial ischemia, <span class="speceff-life">MI</span>, ventricular tachycardia, ventricular fibrillation, chest pain/tightness/heaviness, palpitations. <span class="typehead"> GI:</span>  Dry mouth, nausea, vomiting, diarrhea. <span class="typehead">Respiratory:</span> Dyspnea. <span class="typehead">Skin:</span> Flushing. <span class="typehead">Endocrine:</span> Hot flashes. 
      <h1><a name="interactions">Interactions</a></h1><span class="typehead">Drug:</span>
<b>Propranolol</b> may increase concentrations of rizatriptan, use smaller rizatriptan doses; <b>dihydroergotamine,</b>
<b>methysergide,</b> other 5-<span class="classification">ht</span>
<sub>1</sub>
<span class="classification">agonists</span> may cause prolonged vasospastic reactions; <span class="classification">ssris</span> have rarely caused weakness, hyperreflexia, and incoordination; <span class="classification">maoi</span>s should not be used with 5-HT<sub>1</sub> agonists. <span class="typehead">Herbal:</span>
<b>St. John's wort</b> may increase triptan toxicity. 
      <h1><a name="pharmaks">Pharmacokinetics</a></h1><span class="typehead">Absorption:</span> 45% of oral dose reaches systemic circulation. <span class="typehead">Peak:</span> 11.5 h for oral tabs; 1.62.5 h for orally disintegrating tablets. <span class="typehead">Metabolism:</span> Metabolized via oxidative deamination by monoamine oxidase A. <span class="typehead">Elimination:</span> Excreted primarily in urine (82%). <span class="typehead">Half-Life:</span> 23 h. 
      <h1><a name="nursing"><span class="implictitle">Nursing Implications</span></a></h1>
<p><span class="adeffecttitle">Assessment &amp; Drug Effects</span></p>
<ul>
<li>Monitor cardiovascular status carefully following first dose in patients at risk for CAD (e.g., postmenopausal women, men
            over 40 years old, persons with known CAD risk factors) or coronary artery vasospasms.
         </li>
<li>ECG is recommended following first administration of rizatriptan to someone with known CAD risk factors.</li>
<li>Report immediately to physician: chest pain or tightness in chest or throat that is severe or does not quickly resolve.</li>
<li>Monitor periodically cardiovascular status with continued rizatriptan use.</li>
</ul>
<p><span class="eductitle">Patient &amp; Family Education</span></p>
<ul>
<li>Do not exceed 30 mg (three doses) in 24 h.</li>
<li>Allow orally disintegrating tablets to dissolve on tongue; no liquid is needed.</li>
<li>Contact physician immediately if any of the following develop following rizatriptan use: symptoms of angina (e.g., severe
            and/or persistent pain or tightness in chest or throat), hypersensitivity (e.g., wheezing, facial swelling, skin rash, or
            hives), abdominal pain.
         </li>
<li>Report any other adverse effects (e.g., tingling, flushing, dizziness) at next physician visit.</li>
<li>Do not breast feed while taking this drug without consulting physician.</li>
</ul>
<hr/>
<p><span class="footer">Common adverse effects in <i>italic</i>, life-threatening effects <u>underlined</u>; generic names in <b>bold</b>; classifications in <small>SMALL CAPS</small>; <img border="0" src="../images/maple.gif"/> Canadian drug name; <img border="0" src="../images/pr.gif"/> Prototype drug</span></p>
</body>